3-methyl-6-phenylimidazo[1,2-a]pyridine | 1284210-66-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-methyl-6-phenylimidazo[1,2-a]pyridine
• 英文别名: 3-methyl-6-phenylimidazo[1,2-α]pyridine
• CAS: 1284210-66-7
• 化学式: C₁₄H₁₂N₂
• 分子量: 208.263
• InChiKey: RLZBWKUWVRMUDB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  17.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  tert-butyl N-(5-phenylpyridin-2-yl)-N-prop-2-ynylcarbamate 在 potassium tert-butylate 作用下， 以 四氢呋喃 为溶剂， 反应 0.08h， 以59%的产率得到3-methyl-6-phenylimidazo[1,2-a]pyridine
  参考文献：
  名称：

  A Base Promoted Cyclization of N-Propargylaminopyridines. Synthesis of Imidazo[1,2-a]pyridine Derivatives

  摘要：

  A base promoted cyclization of the protected N-propargylaminopyridines was shown to be an efficient method for the preparation of imidazo[1,2-a] pyridine derivatives. The reactions were carried out with a small excess of base, at room temperature or slightly above producing the heterocyclic products in moderate to good yields. The stereoelectronic properties of substituents on the pyridine ring were shown to influence the cyclization process.

  DOI：

  10.1021/ol200508x

文献信息

• MTA-Cooperative PRMT5 Inhibitors
  申请人：Mirati Therapeutics, Inc.

  公开号：US20210078994A1

  公开（公告）日：2021-03-18

  The present invention relates to compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

  本发明涉及抑制蛋白精氨酸N-甲基转移酶5（PRMT5）活性的化合物。具体而言，本发明涉及化合物、药物组合物和使用方法，例如使用本发明的化合物和药物组合物治疗癌症的方法。
• MTA-cooperative PRMT5 inhibitors
  申请人：Mirati Therapeutics, Inc.

  公开号：US11479551B2

  公开（公告）日：2022-10-25

  The present invention relates to compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity. In particular, the present invention relates to compounds of Formula (I) to pharmaceutical compositions comprising compounds of Formula (I) and to methods of use thereof, such as methods of treating cancer using the compounds of Formula (I) and pharmaceutical compositions comprising those compounds.

  本发明涉及抑制蛋白精氨酸 N-甲基转移酶 5（PRMT5）活性的化合物。特别是，本发明涉及式 (I) 的化合物 涉及包含式（I）化合物的药物组合物及其使用方法，例如使用式（I）化合物和包含这些化合物的药物组合物治疗癌症的方法。
• Synthesis of Imidazo[1,2-<i>a</i>]pyridines: “Water-Mediated” Hydroamination and Silver-Catalyzed Aminooxygenation
  作者：Darapaneni Chandra Mohan、Sadu Nageswara Rao、Subbarayappa Adimurthy

  DOI：10.1021/jo3025303

  日期：2013.2.1

  Aqueous syntheses of methylimidazo[1,2-a]pyridines without any deliberate addition of catalyst are reported. Imidazo[1,2-a]pyrazine and imidazo[2,1-a]isoquinoline were also obtained in good yields under similar conditions. With acetonitrile as solvent, Ag-catalyzed intra-molecular aminooxygenation produced imidazo[1,2-a]pyridine-3-carbaldehydes in moderate to good yields.
• Water mediated deprotective intramolecular hydroamination of N-propargylaminopyridines: synthesis of imidazo[1,2-a]pyridines
  作者：Darapaneni Chandra Mohan、Niraj B. Sarang、Subbarayappa Adimurthy

  DOI：10.1016/j.tetlet.2013.08.112

  日期：2013.11

  Metal-free synthesis of substituted imidazole [1,2-alpha]dpyridines from deprotective N-(prop-2-yn-1-yl)pyridin-2-amines in water is elucidated. Electron releasing substituents on pyridine ring provided pure products in quantitative yields without separation by column chromatography. (C) 2013 Elsevier Ltd. All rights reserved.